STOCK TITAN

RCUS Form 144 filing: planned sale of 100,000 shares on NYSE

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Arcus Biosciences (RCUS): Notice of proposed sale under Form 144. A security holder filed to sell 100,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of $1,988,000. The approximate sale date is 10/28/2025.

The shares were originally acquired from the issuer in a private transaction on 05/29/2015, with payment on the same date. Shares outstanding were 106,430,976, providing scale context for the proposed sale.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did Arcus Biosciences (RCUS) disclose in this Form 144?

A holder plans to sell 100,000 shares of Class A common stock with an aggregate market value of $1,988,000.

When is the planned sale date for the RCUS shares?

The filing lists an approximate sale date of 10/28/2025.

Which broker will handle the proposed RCUS share sale?

The broker is Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282.

On which exchange are the RCUS shares listed for this sale?

The filing names the NYSE.

How many RCUS shares are outstanding for context?

The filing shows 106,430,976 shares outstanding.

When and how were the shares to be sold originally acquired?

They were acquired from the issuer in a private transaction on 05/29/2015, with payment on the same date.
Arcus Bioscience

NYSE:RCUS

View RCUS Stock Overview

RCUS Rankings

RCUS Latest News

RCUS Latest SEC Filings

RCUS Stock Data

2.78B
88.04M
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD